RxDoctor Payments Data

Andrea Plauche

Psychiatric/Mental Health · Baton Rouge, LANPI 1518278589

Payments from drug & device makers

$5,221in general payments, 2019–2025

Across 277 payments — averaging $18.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corium, LLC$1K
  • AbbVie$685
  • Johnson & Johnson$469
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$462
  • Takeda Pharmaceuticals U.S.A., Inc.$354
  • Alkermes, Inc.$351
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$4,97095%
  • Education$2525%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,221 in reported general payments places this provider in the 85th percentile of 615 psychiatric/mental health providers in Louisiana.

See all psychiatric/mental health providers in Louisiana

Medicare billing

Part B allowed, 2024
$30,338
Medicare patients
129
Services billed
390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate83$672,095
Invega SustennaPaliperidone Palmitate104$347,886
Abilify MaintenaAripiprazole33$92,572
VraylarCariprazine Hcl16$23,159
NuedextaDextromethorphan Hbr/Quinidine14$21,563
TrintellixVortioxetine Hydrobromide11$10,309
Clozapine207$6,038
Divalproex Sodium ErDivalproex Sodium177$5,877
RisperdalRisperidone11$4,369
Quetiapine Fumarate277$3,382
Venlafaxine Hcl ErVenlafaxine Hcl91$2,717
Trazodone Hcl239$2,713
Aripiprazole108$2,649
Fluphenazine Hcl18$2,447
Divalproex Sodium142$2,392

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$34$672,09583 claims
Johnson & JohnsonInvega Sustenna, Risperdal$469$352,255115 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$301$92,57233 claims
AbbVieVraylar$685$23,15916 claims
Avanir Pharmaceuticals, Inc.Nuedexta$44$21,56314 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$354$10,30911 claims
Almatica Pharma LLCSertraline Hcl$59$833120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 615 psychiatric/mental health providers in Louisiana.

Other psychiatric/mental health in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →